Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups
I. Determine the impact on overall survival of patients with non-MYCN neuroblastoma below 18
months of age as compared to neuroblastoma patients above 18 months of age.
Archived DNA samples are analyzed for segmental chromosome aberrations by multiplex
ligation-dependent probe amplification (MLPA), a polymerase chain reaction (PCR)-based
technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and
17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
Time Perspective: Retrospective
Overall survival (OS)
Estimated by the Kaplan-Meier method.
From the date of diagnosis to the date of death from any cause, assessed up to 5 years
Children's Oncology Group
United States: Institutional Review Board
|Children's Oncology Group||Arcadia, California 91006-3776|